Clinical trial NCT05797948: GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Official title: Prospective, Single-center, Single-arm, Open-label Study of Obinutuzumab, Zanubrutinib and Lenalidomide Sequential CD19/CD22 CAR-T in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Keywords: Humanized anti-CD20 monoclonal antibody
BTK Inhibitor
Immunomodulators
CAR-T
Lead sponsor: The First Affiliated Hospital of Soochow University
Sponsor class: OTHER
First posted: 2023-04-04
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study intends to use Obinutuzumab, Zanubrutinib, and Lenalidomide sequential CD19/CD22 CAR-T in the treatment of Relapsed or Refractory B-cell Non-Hodgkin Lymphoma patients. The main purpose of this study is to explore a new treatment mode for R/R B-NHL patients and observe the efficacy and safety of this treatment regimen.

Detailed description: The study will start with 2-4 cycles of combination chem-free therapy with obinutuzumab, zanubrutinib and lenalidomide, followed by sequential CAR-T therapy. CAR-T therapy with AZA + FC (Azacitidine +Fludarabine +Cyclophosphamide) conditioning regimen. Targets of CAR-T cells are CD19/CD22. In this clinical trial, ORR, CRR, OS, PFS, AE and other indicators were used to observe the safety and efficacy of this sequential therapy.

Eligibility criteria: Inclusion Criteria:

1. Histologically confirmed CD22 + and/or CD19 + aggressive B-cell non-Hodgkin lymphoma (NHL), including the following types as defined by World Health Organization (WHO) 2016:

   Diffuse large B-cell lymphoma (DLBCL); High grade B-cell lymphoma (HGBL); Primary mediastinal large B-cell lymphoma(PMBCL); T cell/histiocyte-rich large B-cell lymphoma (THRBCL); High grade follicular cell lymphoma Grade 3b (3bFL); Mantle cell lymphoma (MCL) except indolent; Other aggressive B-cell lymphomas.
2. Disease refractory to first-line therapy or early relapse within 12 months of last treatment.
3. Relapse or progressive disease (PD) ≥ 3 months after targeted CD19 therapy including CD19 CAR T cells or anti-CD19/anti-CD3.
4. Successful leukapheresis assessment and T-cell preculture.
5. Life expectancy \> 3 months.
6. Appropriate organ function:

   Creatinine \< 1.6 mg/dL (140 µmol/L) or creatinine clearance ≥ 60ml/min; Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) \< 3 × upper limit of normal; Bilirubin \< 2.0 mg/dL unless subject has Gilbert 's syndrome (\< 3.0 mg/dL); Pulmonary reserve ≤ Grade 1 dyspnea and SPO2 \> 91%; Cardiac ejection fraction ≥ 50% in the absence of oxygen, no evidence of pericardial effusion as determined by echocardiogram (ECHO), and no clinically significant electrocardiogram (ECG) findings.
7. Adequate bone marrow reserve was defined as:

   Absolute neutrophil count (ANC) \> 1000/mm3; Absolute lymphocyte count (ALC) ≥ 300/mm3; Platelet count ≥ 50,000/mm3. Hemoglobin \> 7.0 mg/dL.
8. Measurable or evaluable lesions according to "IWG response criteria for malignant lymphoma" (Cheson 2014).
9. Patients have the ability to understand and are willing to provide written informed consent.

Exclusion Criteria:

1. severe liver and kidney dysfunction (alanine aminotransferase, bilirubin, creatinine \> 3 times the upper limit of normal);
2. the presence of structural heart disease, and lead to clinical symptoms or abnormal heart function (NYHA ≥ 2);
3. uncontrolled active infection;
4. the presence of other tumors requiring treatment or intervention;
5. the current or expected need for systemic corticosteroid therapy;
6. pregnant or lactating women.
7. Other psychological conditions that prevent patients from participating in the study or signing informed consent;
8. According to the investigator 's judgment, the subject is unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or fail to meet the requirements for participation in the study.

Primary outcomes:
measure: Overall response rate (ORR) after GZL therapy
timeFrame: At the end of GZL therapy (2-4 cycles, each cycle is 21days)
measure: Complete response rate (CRR) after CAR-T
timeFrame: Within 3 months after CAR-T therapy
measure: Progression-free survival (PFS) after CAR-T
timeFrame: up to 24 months after the end of last patient's treatment
Secondary outcomes:
measure: Incidence of treatment-emergent adverse events, treatment-related adverse events and serious adverse events
timeFrame: Initiation of GZL therapy until 30 days after CAR-T therapy
measure: Overall response rate (ORR) after CAR-T
timeFrame: Within 3 months after CAR-T therapy
measure: Overall survival (OS) after CAR-T
timeFrame: up to 24 months after the end of last patient's treatment
measure: Duration of Response(DOR) after CAR-T
timeFrame: up to 24 months after the end of last patient's treatment
Other outcomes:
Locations:
city: Suzhou
country: China
facility: the First Affiliated Hospital of Soochow University
state: Jiangsu
Study officials:
References: